ArticleLaryngoscope investigative otolaryngology2025
Impact of the 2015 American Thyroid Association Guidelines on Treatment of Low-Risk Thyroid Cancer.
Article in Laryngoscope investigative otolaryngology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The 2015 American Thyroid Association (ATA) guidelines recommended lobectomy for management of low-risk differentiated thyroid carcinomas (DTC), aiming to mitigate overtreatment. The primary objective of this study was to assess the impact of the 2015 ATA guidelines on the rates of lobectomy versus total thyroidectomy for the treatment of low-risk DTC, using the Surveillance, Epidemiology, and End Results (SEER) 17 database. Our secondary objectives were to examine the modifying effects of tumor size on the change in the rates of lobectomy between the pre- and post-guideline periods and to identify factors that are associated with the use of lobectomy in the post-guideline period. Methods: A retrospective cohort analysis of adults diagnosed with low-risk DTC from 2011 to 2020 was conducted using the SEER 17 database. Logistic regression assessed the likelihood of lobectomy and total thyroidectomy before and after guideline implementation, including size-stratified and post-guideline subgroup analyses. Results: Among 61,078 patients, lobectomy rates increased from 16% pre-guideline to 25% post-guideline (aOR 1.81, 95% CI 1.74-1.89). Lobectomy increased across both T1 and T2 tumors; post-guideline subgroup analysis indicates T2 tumors were less likely to receive lobectomy than T1 tumors. Conclusions: The use of lobectomy for treatment of low-risk DTC has significantly increased since the publication of the 2015 ATA guidelines. However, total thyroidectomy remains the predominant treatment. Level of Evidence: Level 3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.